Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Genentech, Inc.; Janssen, Lilly, and Pharmacyclics LLC, an AbbVie Company.

Medical Crossfire®: How Are We Meeting the Needs of Patients With CLL Across Lines of Care?

Release Date: September 27, 2021
Expiration Date: September 27, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in hematologic malignancies who will evaluate the efficacy and safety of therapies used for the management of CLL across the disease spectrum, discuss the role of minimal residual disease in clinical trials and daily practice, examine the factors that influence treatment decision-making, and assess strategies to monitor, mitigate, and manage treatment-related adverse events. Through case studies and lively panel discussions, various evidence-based approaches to the personalized management of patients with CLL will be put into clinical context.

This educational activity is an archive of a live virtual symposium held on September 9, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Genentech, Inc.; Janssen, Lilly, and Pharmacyclics LLC, an AbbVie Company.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with chronic lymphocytic leukemia. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with chronic lymphocytic leukemia are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine risk stratification methods in patients with CLL and application of patient risk categories for treatment identification
  • Integrate evolving practices in the management of patients with CLL through multiple lines of therapy, integrating the influence of previous regimens on subsequent decision-making
  • Discuss the role of MRD testing as a tool for prognosis and treatment selection in patients with CLL
  • Evaluate strategies to proactively mitigate and manage treatment-related AEs that occur with current and emerging approaches, including combination treatment strategies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Anthony Mato, MD, MSCE
Anthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant research support: TG Therapeutics, Pharmacyclics, Adaptive, Abbvie, Acerta/AZ, Sunesis, Loxo, Regeneron, DTRM; Consultant: TG Therapeutics, Pharmacyclics, Adaptive, Abbvie, Acerta, Sunesis, Loxo, Regeneron, J and J, Celgene; Other: TG Therapeutics / Celgene = DSMB.

Nitin Jain, MD
Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision BioSciences, Aprea Therapeutics, Fate Therapeutics; Consultant: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics, ADC Therapeutics.

William G. Wierda, MD, PhD
William G. Wierda, MD, PhD
D.B. Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: GSK/Novartis, Abbvie, Genentech, Pharmacyclics LLC, AstraZeneca/Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Inc., Cyclacel, Loxo Oncology, Inc., Janssen, Xencor.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By